investment for a safe, long-term treatment for gastroparesis is being provided by Cincinnati, Ohio-based CinDome Pharma, which has raised $40 million in Series B extension investment.
Investors
- Perceptive Advisors
- CinRx Pharma
- bringing the total sum to $59M
Use of funds
With the money, the business plans to position itself for registrational trials while continuing to enroll and assess patients with diabetic gastroparesis in the Phase 2 envision3D research using deudomperidone.
About CinDome
CinDome is committed to developing a treatment that is safe, effective, and bearable for those who suffer from the debilitating effects of long-term gastroparesis. Deudomperidone (CIN-102) is an engineered version of domperidone, a well-known D2/D3 antagonist that is not authorized for use in the United States but is the first-line therapy for gastroparesis globally.
